Corcept Therapeutics/CORT

$23.51

-1.3%
-
1D1W1MYTD1YMAX

About Corcept Therapeutics

Corcept Therapeutics Incorporated is a commercial-stage company, which is engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, exicorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.

Ticker

CORT

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Joseph Belanoff

Employees

352

Headquarters

Menlo park, United States

CORT Metrics

BasicAdvanced
$2.47B
Market cap
24.96
P/E ratio
$0.95
EPS
0.49
Beta
-
Dividend rate
$2.47B
0.48575
$34.28
$20.87
1.33M
4.389
4.315
19.596
17.62%
21.05%
20.65%
24.964
5.112
4.861
4.866
19.431
20.04%
9.04%
10.88%
3.63%

What the Analysts think about CORT

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 5 analysts.
82.05% upside
High $61.00
Low $35.00
$23.51
Current price
$42.80
Average price target

CORT Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
23.11% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$135.4M
9.55%
Net income
$31.3M
0%
Profit margin
23.11%
-8.73%

CORT Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 8.53%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
$0.14
$0.25
$0.28
$0.28
-
Expected
$0.19
$0.15
$0.22
$0.26
$0.23
Surprise
-27.59%
66.67%
28.24%
8.53%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Corcept Therapeutics stock?

Corcept Therapeutics (CORT) has a market cap of $2.47B as of April 13, 2024.

What is the P/E ratio for Corcept Therapeutics stock?

The price to earnings (P/E) ratio for Corcept Therapeutics (CORT) stock is 24.96 as of April 13, 2024.

Does Corcept Therapeutics stock pay dividends?

No, Corcept Therapeutics (CORT) stock does not pay dividends to its shareholders as of April 13, 2024.

When is the next Corcept Therapeutics dividend payment date?

Corcept Therapeutics (CORT) stock does not pay dividends to its shareholders.

What is the beta indicator for Corcept Therapeutics?

Corcept Therapeutics (CORT) has a beta rating of 0.49. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Corcept Therapeutics stock price target?

The target price for Corcept Therapeutics (CORT) stock is $42.8, which is 82.05% above the current price of $23.51. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Corcept Therapeutics stock

Buy or sell Corcept Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing